Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Illness01:17

Classification of Illness

8.4K
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
8.4K
Marcia's Theory of Identity Status01:26

Marcia's Theory of Identity Status

1.2K
James Marcia's identity status model provides a framework for understanding how adolescents navigate identity formation through varying degrees of exploration and commitment. Marcia's model builds on Erik Erikson's theories of psychosocial development, focusing specifically on how adolescents reconcile individual aspirations with societal expectations. His model describes identity formation as a dynamic process where adolescents move between different states depending on their level...
1.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same author

Immuno-Proteomic Features Associated to Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Neurological research and practice·2026
Same author

Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disorders.

Journal of neurology·2026
Same author

Expert Panel Consensus Guidelines of the German Society of Neuroradiology on the Use of Magnetic Resonance Imaging in the Diagnosis and Monitoring of Multiple Sclerosis.

Clinical neuroradiology·2026
Same author

Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.

The journal of headache and pain·2026

Related Experiment Video

Updated: Dec 18, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K

The transitional phase of multiple sclerosis: Characterization and conceptual framework.

Ingo Kleiter1, Ilya Ayzenberg2, Joachim Havla3

  • 1Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Multiple Sclerosis and Related Disorders
|June 15, 2020
PubMed
Summary
This summary is machine-generated.

The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is gradual, not abrupt. Further research is needed to define this transitional MS phase and identify interventions to delay progression.

Keywords:
BiomarkerDisease courseDisease modifying therapyProgressive multiple sclerosisTrial design

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.0K

Related Experiment Videos

Last Updated: Dec 18, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.5K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.0K

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Disease Progression

Background:

  • The conversion from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is a gradual process, lacking a defined threshold.
  • A transitional phase between RRMS and SPMS is hypothesized but poorly understood.
  • Current understanding of transitional multiple sclerosis (MS) lacks characterization of patient properties, disease course, and therapeutic strategies.

Purpose of the Study:

  • To review existing knowledge on the transitional phase of multiple sclerosis.
  • To characterize patient properties, disease course, and therapeutic interventions relevant to transitional MS.
  • To propose designs and criteria for a prospective clinical study in transitional MS patients.

Main Methods:

  • Literature review of current evidence on transitional MS.
  • Analysis of patient characteristics and disease progression in the transitional phase.
  • Exploration of potential diagnostic markers and therapeutic targets.

Main Results:

  • The conversion to SPMS is a continuum, suggesting a distinct transitional MS phase.
  • Transitional MS is poorly defined regarding clinical features, pathogenesis, and diagnostic markers.
  • Evidence for interventions delaying RRMS to SPMS conversion in this phase is limited.

Conclusions:

  • The transitional phase of MS requires further investigation to improve patient management.
  • Prospective studies are essential to define transitional MS and identify effective treatments.
  • Better characterization of transitional MS could lead to earlier diagnosis and intervention, potentially delaying disease progression.